StockNews.AI
BCTX
StockNews.AI
1 min

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

1. BriaCell announces preclinical Bria-OTS+ data presentation at SITC 2025. 2. Event scheduled for November 7-9, 2025, in National Harbor, MD. 3. Presentation could showcase innovative cancer vaccine strategies and innate immunity. 4. Poster will be available post-presentation on BriaCell's website.

5m saved
Insight
Article

FAQ

Why Bullish?

Presentation at a significant industry conference may attract investor attention and improve BCTX's market perception, similar to the positive price movements for biotech stocks following favorable news or presentations at major conferences. Historical instances, like the upward movement of stocks such as Moderna (MRNA) after key presentations, support this view.

How important is it?

The article's focus on BriaCell's presentation at SITC 2025 directly relates to upcoming developments that could validate their innovative therapies, impacting shareholder confidence and investment decisions.

Why Short Term?

In the immediate aftermath of the presentation in November 2025, investor sentiment and stock price could be positively influenced as news spreads. Short-term price movements often follow significant announcements or presentations in biotech.

Related Companies

MRNANKCLVS
October 03, 2025 07:30 ET  | Source: BriaCell Therapeutics Corp. PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. The details are listed below. Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance Abstract Number: 353 Location: Prince George ABC Exhibit Halls Gaylord National Resort and Convention CenterDate: Friday, Nov. 7, 2025 Following the presentation, a copy of the poster will be made available at https://briacell.com/scientific-publications/. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting a poster at the SITC 2025 Annual Meeting, and the contents of such poster, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com Investor Relations Contact:investors@briacell.com

Related News